TIANMU pharmaceutical industry repeatedly criticized five years of three losses in the market bad

Sina Financial client: And the bull takes off! Profit year by selling assets and other non-recurrent gains and losses; After the release of the risk of the withdrawal of the market, the lawyer has begun to openly solicit investors to claim the rights of the listed company TIANMU pharmaceutical industry since 2014 has been bad. May, due to shareholders "pinch rack" to recall alone Dong, August, by the Shanghai SSE [Weibo] to inform the criticism, September, by the Zhejiang Securities Regulatory bureau ordered to correct; November, bulletin by the Securities and Futures Commission [micro-BO] file for investigation; December, release risk tips ... In addition to facing unpredictable penalties from regulators, the company could face investor claims. In the continued downturn in operating performance, have to rely on investment and asset transfer to maintain the income of the reality, Tianmu pharmaceutical industry investors are looking forward to the only positive, leaving only the unknown prospects of the "restructuring." Beijing News reporter ZHANGQUANWI published a risk hint, the company said it did not know the reason for the December 14 night, the listed company TIANMU Pharmaceutical Industry Bulletin said the company for alleged violations of securities laws and regulations, is currently under the China Securities Regulatory Commission for investigation, and the risk of a moratorium on listing. The company announced that "in case of fraud or disclosure of significant information, according to the" Shanghai Stock Exchange [micro-blog] stock Listing Rules (revised 2014) ", the company's shares will be Shanghai stock Exchange [micro-BO] implementation risk warning, and suspend the listing, please investors pay attention to investment risk. "After the announcement, about the company for what reason by the supervision of the investigation, become a stock bar investors hot topic." "Will it be the Black swan?" Do you want to withdraw? "A lot of people are obsessed with this. Some people complain about the company, the bulletin is written hazy ambiguous, irresponsible to shareholders: "What is suspected of violating securities laws and regulations?" "" Really do not know, we do not know. December 18, the Tianmu Pharmaceutical Securities Department told the Beijing News reporter, up to now is still not clear to the company to investigate the case. "What the company knows is already in the Bulletin No. 14th." The person told reporters that the company received the CSRC at the end of November notice. According to the latest rules of information disclosure in 2014, if a listed company receives a case notice, every month we have to carry out a notice of risk notification. "The company is only disclosed in accordance with the regulations. The securities department said the company had no judgment as to when the findings might be known. November 27, Tianmu Pharmaceutical issued a notice that has been a case for investigation by the SFC, the company did not disclose the details of the investigation. "The investigation may be very short, possibly very long, and we are not clear about it," he said. They did not come to our company, we do not know how the specific investigation. The securities department said. "We can only guess the cause of the investigation without disclosing more details," he said. "Shanghai Jie Sai law firm lawyer Wang Zhibin told the Beijing News reporter, the Securities and Futures Commission investigation, there is a great possibility is not based on known facts, but previously not identified irregularities or new discoveries." "In the last 7 years, daysThe head of the pharmaceutical industry has been punished 4 times, of which two of the penalties were withdrawn. Shanghai Hua Rong law firm lawyer Xu Feng told reporters, Tianmu pharmaceutical industry This release of the risk of delisting "may just be a routine matter", but the hint of risk this behavior will affect investors to the company's judgment. "I don't think investors should read too much into this," Xu Feng said. "Everything should await the outcome of the SFC's final deal." "The company itself doesn't know what it's doing, because it's too much to commit." "Some investors joked. "Gossip" constantly, repeatedly criticized public information that since August this year, the days of medicine has been due to a variety of issues by the regulatory authorities to inform the criticism. This August, the SSE to the Tianmu pharmaceutical industry issued a notification of the letter of intent, the letter of intent pointed out that the company's three major issues, including "for the Huangshan Pharmaceutical Co., Ltd. for the overall relocation of the interim report to replace temporary announcements"; and refuses to cooperate with the daily supervision work of the Shanghai Stock Exchange. "By refusing to cooperate with the regulatory work, this question alone is questionable." If the company itself is convinced that there is no problem, it should be unreasonable to refuse to cooperate with the supervision. A capital market analyst said, "A listed company does not cooperate with the day-to-day supervision of the regulatory department, and from another point of view, the company's current internal governance has been very confusing." "One months after the September 26, the Tianmu pharmaceutical industry again announced that the company was the Zhejiang Provincial certificate and Regulatory Bureau ordered rectification." According to the Zhejiang Securities and Regulations Bureau issued the "decision to order corrective measures" show: "The company did not disclose a significant omission of information disclosure in its 2013 annual report, when it disclosed that its 60% stake in Shenzhen, a holding subsidiary, had been transferred to the shareholders of Liang. Shenzhen is still the company as a merger within the scope of the subsidiary, the relevant financial statements have significant errors. It is worth mentioning that, as early as last year, the Tianmu pharmaceutical industry was notified by the regulation and fined a fine of $300,000 for the letter. Subject to the impact of the exit risk, the days of the pharmaceutical industry recently tumbled. TIANMU pharmaceutical industry After the announcement, lawyers have begun to openly solicit investors for rights claims. Wang Zhibin, a lawyer at Shanghai Jie Sai Law firm, told reporters that dozens of investors who had bought the Tianmu pharmaceutical industry before December 27 had registered. "After the SFC's investigation and processing results come out, we can formally take legal proceedings." Wang Zhibin said, "from the two years of the SFC to deal with the general progress of listed companies, this process will probably have to wait six to one year or so." "Restructuring" repeatedly failed, is still expected to new restructuring July 28, the days of the pharmaceutical industry announced that "due to the lack of star science and technology on the issue of price and other issues to reach agreement, a major asset restructuring again terminated." The planned restructuring failed and said no major asset restructurings were planned for 6 months. Suspended for three months to concentrate on the narrative of the "reorganization" story temporarily stranded. This is the TIANMU pharmaceutical industry since 2010For the fourth time since the reorganization failed. Public information indicates that the reorganization of the TIANMU pharmaceutical industry has failed many times. Company and star Technology restructuring began this year July 18, the same day, its actual control of Yang Zongchang and star Technology signed an agreement, Tianmu pharmaceutical industry to issue shares, pay cash for the way the acquisition of the latter equity. As early as April 29 this year, the Tianmu Pharmaceutical Co., Ltd. has announced the agreement with Hunan business and Kang Pharmaceutical Electronic Commerce Limited company, plans to issue shares and pay cash in the way, the acquisition of Hunan Business and health Equity, and raise supporting funds for follow-up production and operation. The restructuring plan ended in failure. July 22, Tianmu Pharmaceutical issued a notice, with the previous intention to restructure the party of the whole continent Pharmaceutical Group's reorganization plan to terminate, according to the former plan, Tianmu pharmaceutical to deal with each other to issue shares and pay cash to buy Hunan business and Health Pharmaceutical E-commerce Co., Ltd., while raising supporting funds. "Tianmu pharmaceutical industry is a gossip a lot of performance, but has been attracting private equity big boss linger." Investors who are concerned about the Tianmu pharmaceutical industry commented that the reason is that the Tianmu pharmaceutical industry was previously expected by the market for a long "restructuring shares" identity. April 2012, by Song Xiaoming [Weibo] created by the Great Wall Guo Hui's four funds Shenzhen long sinks, Shenzhen city, Shenzhen Cheng Hui, Tianjin Long exchange through the licensing and judicial transfer to obtain the control of the days of the pharmaceutical industry; 2013, Song Xiaoming due to internal struggle to withdraw from the Tianmu pharmaceutical industry, by Yang Zongchang, in April 2014, Song Xiaoming a comeback, through the two-tier market, again killed into the Tianmu pharmaceutical industry, but can not dominate the listed companies. "A few big private equity giants converge on the sky, throwing a huge sum, not empty-handed." I think that after a period of transfer of chips, it should be again to suspend the reorganization, and the current performance of the TIANMU, also have to reorganize. "Investors who are concerned about the TIANMU pharmaceutical industry are still looking forward to the prospect of restructuring the target." Data show that the days of the pharmaceutical industry in recent years the performance is dismal. 2009, 2010, the days of the head of the pharmaceutical industry loss of 75.32 million yuan and 8.83 million yuan, May 2011, the days of the head of the pharmaceutical industry, June to October, the original director Liang, Mechin, Yenchunyu, Wu Xiaobo [Weibo], Zhengtao resigned successively. In the May 2013, the company was "tipped ladies" by 2011 earnings, but not because of its performance, but because of the sale of its subsidiaries to gain revenue. In the company's success "tipped Ladies" at the same time, ye tan [micro-bo] and other three independent directors and chairman Song Xiaoming and vice chairman Li Hulin 5 people announced the resignation. Data show that in 2012, the company again loss of 88.84 million yuan, 2013 days head of the net profit of 2.1084 million yuan, again with meager profit from CAP, but the main business is still loss, profit mainly depends on investment income and asset transfer proceeds. (Original title: Five years of the three-day head of the drug industry was "back to market" bad)